MedTrace Logo

AMG 334 20160172 Pediatric Migraine PK Study.

NCT03499119 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2024-05-28

Study results available
· View outcomes & findings →

Summary

AMG 334 20160172 Pediatric Migraine PK Study.

Conditions

Interventions

DRUG

AMG 334 Dose 1

Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3. Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2

DRUG

AMG 334 Dose 2

Subjects weighing weight threshold or more at Day 1 will be randomized to either Dose 1 or Dose 2.

DRUG

AMG 334 Dose 3

Subjects weighing less than weight threshold at Day 1 will be randomized to either Dose 1 or Dose 3.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-04
Primary Completion
2021-11-23
Completion
2021-11-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03499119 on ClinicalTrials.gov